Biologic injections in Glendale: where can I get blood-based care?

How do orthobiologics near me work in Glendale?

Orthobiologics means care made from blood, marrow, fat, or donor tissue. Clinics use PRP as the short name for platelet-rich plasma. A clinician draws blood from your arm. After a machine spins it, the platelet-rich part is placed in the sore joint or tendon. Platelets are tiny blood pieces that help form clots and carry healing proteins. Concentrated PRP keeps a larger share of those pieces. That doesn’t prove it will bring more relief.

From Arrowhead and north Glendale, the Peoria clinic is at 13128 N. 94th Drive, just west of Loop 101 at Thunderbird Road. From the south side, Banner Estrella at 9305 W. Thomas Road may be the simpler drive. One number reaches both locations: (602) 837-PAIN.

Ask which location means less time in the car.

What happens at the first visit?

Expect questions and an exam first. You’ll be asked which motion hurts, what eases it, and what you can’t do now. Bring old X-rays if you have them. Wear clothing that makes the sore area easy to examine.

Medical providers are the clinicians who examine you at QC Kinetix. They may discuss regenerative care, a broad name for non-surgical treatment made from blood, marrow, fat, or donor tissue. They may call the aim joint preservation, meaning trying to keep your joint useful before surgery. Ask what will be done, how long it takes, and what you’ll need to do afterward.

You shouldn’t leave wondering what happens next.

What should biologic injections for joint pain cost me?

Get the full price first. Ask what it covers, how many visits are planned, and whether follow-up costs more. Patients often pay for this care themselves. A fuzzy price isn’t good enough, and higher cost doesn’t mean better care.

Ask when you’ll judge the result. Your joint may feel more sore just after care. Find out whether you’ll need a ride or help with chores. Ask about limits on walking, driving, and lifting.

Know the money, time, and work before you agree.

Sources

1. Medicare's national coverage determination states that CMS covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only inside an approved coverage-with-evidence-development clinical study. Every approved study listed under the NCD is a wound-healing study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

2. A cross-sectional study contacted 273 of 317 US centres offering direct-to-consumer stem-cell therapy, posing as a 57-year-old man with knee osteoarthritis. The mean advertised price of a unilateral same-day stem-cell knee injection was $5,156 (SD $2,446; 95% CI $4,550-5,762, n=65) and the mean claimed clinical efficacy was 82% (SD 9.6%; n=36) - a figure the authors describe as a gap between marketing claims and the published literature.

   Piuzzi NS, et al. — The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective.. Journal of Knee Surgery, 2018. DOI: 10.1055/s-0037-1604443.

3. The AAOS patient-education FAQ on orthobiologics states that because orthobiologics are relatively new the evidence supporting their use is LIMITED, that rigorous testing of effectiveness in most orthopedic conditions is lacking, and that preliminary results are encouraging but hard to evaluate. It names tendinopathies such as tennis elbow, pain from early knee osteoarthritis, adjunct healing after rotator cuff repair, and avascular necrosis as the settings where biologic therapies have shown promise, and notes that stem cell treatments not derived from the patient's own body and further manipulated in a laboratory can only be offered inside an FDA-approved clinical trial.

   American Academy of Orthopaedic Surgeons — Orthobiologics (Regenerative Medicine) FAQ. OrthoInfo (AAOS), 2024.

4. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

5. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature Medicine, 2023. DOI: 10.1038/s41591-023-02632-w.